H1-0

Histone H1.0 · P07305 · H1-0 on Sugi Atlas →

0 patent compounds predicted against H1-0, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to H1-0 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure PHASE3ACTIVE_NOT_RECRUITING
Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors PHASE2RECRUITING
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma PHASE2COMPLETED
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) PHASE1/PHASE2NOT_YET_RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes PHASE1COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Intravenously Administered M6229 in Critically Ill Sepsis Patients PHASE1COMPLETED
ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease PHASE1NOT_YET_RECRUITING
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors PHASE1RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins nanCOMPLETED
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors nanRECRUITING
Impact of Air Quality on the Effectiveness of Standard of Care Therapy in Children With Autism Spectrum Disorder: A Prospective Longitudinal Study nanNOT_YET_RECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing nanRECRUITING
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a H1-0 binder may also engage these)

ProteinNameSimilarity
Q5NVN9 1.000 Q5NVN9 →
P10922 1.000 P10922 →
Q0IIJ2 1.000 Q0IIJ2 →
P22844 1.000 P22844 →
P43278 1.000 P43278 →
Q02539 1.000 Q02539 →
Q94972 1.000 Q94972 →
Q6NVM0 1.000 Q6NVM0 →
Q9M5W4 0.999 Q9M5W4 →
Q94555 0.999 Q94555 →
Q24704 0.999 Q24704 →
Q19743 0.998 Q19743 →
P15867 0.998 P15867 →
P06893 0.998 P06893 →
P22845 0.998 P22845 →
P08283 0.997 P08283 →
P43275 0.997 P43275 →
P02255 0.997 P02255 →
P08287 0.996 P08287 →
P15866 0.996 P15866 →
P40265 0.996 P40265 →
P17268 0.996 P17268 →
G3N131 0.996 G3N131 →
P15864 0.995 P15864 →
O01833 0.995 O01833 →
H1-2 Histone H1.2 0.995 landscape →
P02253 0.995 P02253 →
O16277 0.995 O16277 →
D4A3K5 0.995 D4A3K5 →
P23444 0.995 P23444 →